Building the commercial case for veterinary research at the University of Nottingham

Researchers at the University of Nottingham’s School of Veterinary Medicine and Science have developed a biomarker-based approach that detects lameness in dairy cows before visible signs appear. The science was well advanced; the commercial evidence funders was not yet in place. Through the University’s Impact Accelerator programme, Phoenix Ventures (PVL) provided the commercial analysis to close that gap: market, economics, competition and route to market.
The challenge
Lameness affects around three in ten UK dairy cows at any one time and is among the costliest endemic conditions in dairy farming. Dr Laura Randall, Clinical Associate Professor in Ruminant Health and Welfare, and her group had published early evidence that changes in milk can signal lameness before a cow begins to limp, ahead of the cameras and wearables that register gait change once it has happened.
The next stage of funding depended on stronger commercial evidence: market need, routes to market, economic viability across the value chain and competitive differentiation. The University brought deep veterinary expertise, a structured accelerator programme and separately commissioned farmer research. What the project needed alongside these was dedicated commercial capability: an independent test of the opportunity as a business, in the terms funders and future partners use.
Our approach
Working closely with Dr Randall to test assumptions, PVL framed and answered four questions:
Where does value sit? A map of the dairy lameness value chain, from detection and veterinary care to welfare compliance and data, showing who gains from earlier detection.
What is it realistically worth? A range-based economic model that discounts theoretical savings for real farm behaviour, such as how quickly alerts are acted on, before setting indicative price thresholds and market size.
What does it compete with? An assessment of rival technologies by when they detect lameness, not only how accurately, which recast several apparent competitors as potential channel partners.
How should it reach market? A comparison of licensing to an established animal health or diagnostics company, a direct subscription service and a data-platform model.
PVL managed the work end to end, drawing on additional research support, and delivered within the programme’s funding window.
The outcome
Completed: a commercial and economic analysis of around 50 pages, including the value chain, economic model with sensitivity testing, competitive landscape and draft value propositions for farmers, vets, commercial partners and investors.
Recommended: a phased route to market, beginning with a funded commercial pilot to generate validation evidence, followed by partner-led licensing, with the longer-term data opportunity developed once there is scale. The analysis also identified early regulatory and data governance questions to resolve before piloting.
Next: Dr Randall is now using the analysis to plan the project’s next stage.
“Phoenix Ventures brought a clear, practical commercial lens to our research. Tim mapped the value chain, tested the economics, spoke directly with established players in the sector and set out realistic routes to market. That gave us a much sharper view of who would use the technology, why they would pay for it and what evidence we need next. He understood the academic context throughout, while asking the commercial questions that researchers can easily leave until later.”
Dr Laura Randall, Clinical Associate Professor in Ruminant Health and Welfare, University of Nottingham
Why it matters
Promising research often reaches a point where progress depends on commercial evidence that takes dedicated time and market judgement to build. If you are supporting research at a similar stage, we would be glad to compare notes. [Contact Tim Chater]
.png)


Comments